Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Who To Watch In Health Care Policy Under Trump

Executive Summary

From Newt Gingrich to President Barack Obama, speculation about who will be the central figures to watch in US health care policy in the Trump administration occupied panelists at the Partnering for Cures meeting.

You may also be interested in...

Trump’s Election Could Bring ‘Best Of Times’ For Pharma

Obama administration wasn’t bad but had ‘less than thrilling moments,’ BIO exec says; former FDA Commissioner says leadership, not scientific, skill is key attribute for next agency chief.

Trump’s FDA Reform Agenda: Patient-Focused Approvals

A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.

The Trump Rally: GOP Sweep Is Good News For Biopharma – But Don’t Get Carried Away

Wall Street has made up its mind that the Nov. 8 US elections were great for biopharma companies. But is it really that clear cut?


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts